HOME >> BIOLOGY >> NEWS
Researchers isolate key part of cells death signals

d which threaten to grow out of control to form tumors. Certain infection-fighting immune cells also are marked for apoptotic death after a brief active life so that they don't turn their weapons on the body's normal cells.

A "family" of apoptosis-regulating proteins contains both pro-death (including BAK, BIM and BID) and pro-survival members. One pro-survival molecule is called BCL-2, named for the disease it causes B-Cell lymphoma when it is overexpressed in white blood cells, allowing them to accumulate abnormally. BCL-2 performs much of its pro-survival function by binding and sequestering pro-death molecules, preventing them from transmitting a pro-death signal.

Some pro- and anti-apoptosis molecules are generally found on the membrane forming the outside of mitochondria. These are tiny mini-organs in cells that provide energy but also contain a substance that kills cells if it is released into the cell's interior.

One of the crucial signals for apoptosis is a protein called BAK, which resides in an inactive form on the mitochrondrial membrane. When other pro-death signals activate it, BAK changes shape and opens holes in the membrane that release the lethal cytochrome c from the mitochondrion. The pro-survival signal BCL-2 also is found on the membrane, and its function is to keep BAK inactive, preventing cell suicide.

Letai, who is also an instructor in medicine at Harvard Medical School, and his colleagues looked closely at the life-death process by isolating living mitochondria from cells and manipulating them in the laboratory. They devised tests that could show whether molecules like BAK were "activated" that is, carrying out their pro-death function.

BAK can be set into motion in two ways: pro-death signal proteins BID or BIM can bind to BAK, or other pro-death proteins BAD and BIK can flood BCL-2, keeping that pro-survival protein occupied so that BID proteins can evade BCL-2 and bind to BAK, turning it on.'"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
13-Sep-2002


Page: 1 2 3

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers discover why mutant gene causes colon cancer
11. Researchers identify the genomes controlling elements

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Researchers isolate key part cells death signals

(Date:5/21/2013)... at Chicago College of Medicine will study gender differences in ... energy source -- and how changes in fat metabolism play ... 4-year grant from the National Heart, Lung and Blood Institute. ... for energy. These changes may play a major role in ... and women, says E. Douglas Lewandowski, director of the UIC ...
(Date:5/21/2013)... charted the path of insulin action in cells in ... blueprint for understanding what goes wrong in diabetes. ... Professor David James from Sydney,s Garvan Institute of Medical ... of the prestigious journal Cell Metabolism . , ... very important role in the body because it helps ...
(Date:5/20/2013)... is known about the effect of physical education (PE) ... University finds that increasing the amount of time that ... of obesity. , The study represents some of the ... youth obesity, and is forthcoming in the Journal ... of the study can be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 ...
Breaking Biology News(10 mins):Do men's and women's hearts burn fuel differently? 2Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Gym class reduces probability of obesity, study finds for first time 2
(Date:5/21/2013)... May 21, 2013 Alpha Source, ... , will be exhibiting for the 13th consecutive ... Medical Instrumentation (AAMI) 2013 Conference and Expo. The ... distribute, and manufacture healthcare technologies. This year’s event ... Beach, California. , The three-day event draws ...
(Date:5/21/2013)... Raleigh, NC (PRWEB) May 21, 2013 ... and financial services company for clinical trials, announced ... Aggregate Spend Solutions, LLC. Clinverse’s ClinPay® FLS ... automated investigator payment process. SpendMD ™, ... only complete solution for tracking and reporting transfer ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 As ... a strong push within the industry to deliver ... Manufacturing Organizations and pharma companies often means turning ... , Microtablets, developed in collaboration with Sensidose AB ... outsourcing can bring products to market sooner. The ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. ... study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal ... expressing the HER2 oncoprotein," will be presented at ... of Clinical Oncology during the Developmental Therapeutics - ... at 4:15 – 4:30 PM.  The presentation will ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: